×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Heron Therapeutics Inc. (HRTX) NASDAQ

$2.77 (0.17) (-5.78%)

Market Cap: $442.92M

As of 05/10/24 04:00 PM EDT. Market closed.

(HRTX)

Heron Therapeutics Inc. (HRTX)
NASDAQ

$2.77
(0.17) (-5.78%)

Market Cap: $442.92M

As of 05/10/24 04:00 PM EDT. Market closed.

Add to Portfolio

heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be ... read more

COMPANY PROFILE
Sector
Industry
CEO
Barry Quart
Full Time Employees
283
CEO Compensation (Base)
$614,414
CEO Compensation (Total)
$5.99M
URL
Address
4242 Campus Point Ct Ste 200, California, San Diego, 92121.
Sector
Industry
CEO
Barry Quart
Full Time Employees
283
CEO Compensation (Base)
$614,414
CEO Compensation (Total)
$5.99M
Address
4242 Campus Point Ct Ste 200, California, San Diego, 92121.
PRICE CHART FOR HERON THERAPEUTICS INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$3.04
Previous Close
$2.94
Days Range
$2.73 - $3.05
52 week range
$0.50 - $3.22
Volume
1,992,410
Avg. Volume (30 days)
2,557,451
Market Cap
$442.92M
Dividend Yield
-
P/E
-
Shares Outstanding
150,653,158
Open
$3.04
Previous Close
$2.94
Days Range
$2.73 - $3.05
52 week range
$0.50 - $3.22
Volume
1,992,410
Avg. Volume (30 days)
2,557,451
Market Cap
$442.92M
Dividend Yield
-
P/E
-
Shares Outstanding
150,653,158
FINANCIAL STATEMENTS FOR HERON THERAPEUTICS INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR HERON THERAPEUTICS INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Duarte IraEVP, Chief Financial OfficerApr 19, 2024 Option Exercise$2.641,1222,96287,752Apr 19, 2024, 05:48 PM
Peraza LisaVP, Chief Accounting OfficerJan 13, 2024 Option Exercise$2.157561,62555,907Jan 16, 2024, 05:19 PM
Forbes William PEVP, Chief Development OfficerNov 17, 2023 Buy$1.0925,00027,25079,000Nov 21, 2023, 12:19 PM
Forbes William PEVP, Chief Development OfficerNov 16, 2023 Buy$0.9450,00046,99554,000Nov 20, 2023, 10:07 AM
Collard Craig AChief Executive OfficerNov 16, 2023 Buy$0.92150,000137,970186,496Nov 17, 2023, 12:37 PM
Duarte IraEVP, Chief Financial OfficerNov 16, 2023 Buy$0.8985,00075,59985,000Nov 17, 2023, 12:36 PM
Peraza LisaVP, Chief Accounting OfficerJul 25, 2023 Option Exercise$1.5114,74322,26253,198Oct 17, 2023, 07:57 PM
Peraza LisaVP, Chief Accounting OfficerOct 13, 2023 Option Exercise$0.7286061954,822Oct 17, 2023, 07:57 PM
Collard Craig AChief Executive OfficerAug 22, 2023 Option Exercise$1.656921,14236,496Aug 24, 2023, 04:09 PM
Morgan AdamDirectorJul 21, 2023 Buy$1.372,486,7443,406,8396,986,744Jul 25, 2023, 04:22 PM
Szekeres David LeslieEVP, Chief Operating OfficerJul 13, 2023 Option Exercise$1.312,0122,63633,754Jul 17, 2023, 05:51 PM
Peraza LisaVP, Chief Accounting OfficerJul 13, 2023 Option Exercise$1.318601,12725,310Jul 17, 2023, 05:51 PM
Collard Craig AChief Executive OfficerMay 22, 2023 Option Exercise$1.456911,00237,188May 24, 2023, 05:04 PM
Szekeres David LeslieEVP, Chief Operating OfficerApr 13, 2023 Option Exercise$2.882,0125,79529,952Apr 17, 2023, 05:28 PM
POYHONEN JOHNPresident & CCOApr 13, 2023 Option Exercise$2.882,0125,79546,648Apr 17, 2023, 05:27 PM
Peraza LisaVP, Chief Accounting OfficerApr 13, 2023 Option Exercise$2.888602,47723,685Apr 17, 2023, 05:27 PM
MANHARD KIMBERLYEVP, Drug DevelopmentApr 13, 2023 Option Exercise$2.881,4174,08128,330Apr 17, 2023, 05:26 PM
Szekeres David LeslieEVP, Chief Operating OfficerJan 13, 2023 Option Exercise$3.172,0126,37826,150Jan 17, 2023, 05:37 PM
Szekeres David LeslieEVP, Chief Operating OfficerOct 31, 2022 Option Exercise$3.271,6545,41322,348Jan 17, 2023, 05:37 PM
Quart Barry DChief Executive OfficerJan 13, 2023 Option Exercise$3.175,21916,544177,989Jan 17, 2023, 05:36 PM
Quart Barry DChief Executive OfficerOct 31, 2022 Option Exercise$3.271,6555,416163,441Jan 17, 2023, 05:36 PM
POYHONEN JOHNPresident & CCOJan 13, 2023 Option Exercise$3.172,0126,37842,846Jan 17, 2023, 05:36 PM
Peraza LisaVP, Chief Accounting OfficerJan 13, 2023 Option Exercise$3.171,0133,21122,061Jan 17, 2023, 05:35 PM
MANHARD KIMBERLYEVP, Drug DevelopmentJan 13, 2023 Option Exercise$3.172,0126,37823,933Jan 17, 2023, 05:34 PM
MANHARD KIMBERLYEVP, Drug DevelopmentOct 31, 2022 Option Exercise$3.271,6555,41620,131Jan 17, 2023, 05:34 PM
Szekeres David LeslieEVP, Chief Operating OfficerOct 13, 2022 Option Exercise$3.762,0127,56520,694Oct 17, 2022, 04:38 PM
Quart Barry DChief Executive OfficerOct 13, 2022 Option Exercise$3.765,21919,623161,786Oct 17, 2022, 04:38 PM
POYHONEN JOHNPresident & CCOOct 13, 2022 Option Exercise$3.762,0127,56539,044Oct 17, 2022, 04:37 PM
Peraza LisaVP, Chief Accounting OfficerOct 13, 2022 Option Exercise$3.768613,23720,589Oct 17, 2022, 04:36 PM
MANHARD KIMBERLYEVP, Drug DevelopmentOct 13, 2022 Option Exercise$3.762,0127,56518,476Oct 17, 2022, 04:36 PM
Szekeres David LeslieEVP, Chief Operating OfficerJul 13, 2022 Option Exercise$3.012,0126,05616,892Jul 15, 2022, 04:58 PM
Szekeres David LeslieEVP, Chief Operating OfficerApr 29, 2022 Option Exercise$3.841,5055,78213,090Jul 15, 2022, 04:58 PM
Quart Barry DChief Executive OfficerJul 13, 2022 Option Exercise$3.015,21915,709147,237Jul 15, 2022, 04:57 PM
Quart Barry DChief Executive OfficerApr 29, 2022 Option Exercise$3.841,5045,778132,688Jul 15, 2022, 04:57 PM
POYHONEN JOHNPresident & CCOJul 13, 2022 Option Exercise$3.012,0126,05635,242Jul 15, 2022, 04:56 PM
Peraza LisaVP, Chief Accounting OfficerJul 13, 2022 Option Exercise$3.018602,58918,965Jul 15, 2022, 04:55 PM
MANHARD KIMBERLYEVP, Drug DevelopmentJul 13, 2022 Option Exercise$3.012,0126,05614,674Jul 15, 2022, 04:55 PM
MANHARD KIMBERLYEVP, Drug DevelopmentApr 29, 2022 Option Exercise$3.841,5045,77812,376May 04, 2022, 07:01 PM
MANHARD KIMBERLYEVP, Drug DevelopmentMay 03, 2022 Sale$4.761,5047,15410,872May 04, 2022, 07:01 PM
Szekeres David LeslieEVP, Chief Operating OfficerApr 13, 2022 Option Exercise$6.072,01212,21311,585Apr 15, 2022, 05:06 PM
Quart Barry DChief Executive OfficerApr 13, 2022 Option Exercise$6.075,21931,679131,184Apr 15, 2022, 05:05 PM
POYHONEN JOHNPresident & CCOApr 13, 2022 Option Exercise$6.072,01212,21331,440Apr 15, 2022, 05:04 PM
Peraza LisaVP, Chief Accounting OfficerApr 13, 2022 Option Exercise$6.078605,22017,340Apr 15, 2022, 05:03 PM
MANHARD KIMBERLYEVP, Drug DevelopmentApr 13, 2022 Option Exercise$6.072,01212,21310,872Apr 15, 2022, 05:03 PM
Szekeres David LeslieEVP, Chief Operating OfficerJan 13, 2022 Option Exercise$8.302,01216,7007,783Jan 14, 2022, 05:09 PM
Quart Barry DChief Executive OfficerJan 13, 2022 Option Exercise$8.305,21943,318116,635Jan 14, 2022, 05:08 PM
POYHONEN JOHNPresident & CCOJan 13, 2022 Option Exercise$8.302,01216,70027,638Jan 14, 2022, 05:07 PM
Peraza LisaVP, Chief Accounting OfficerJan 13, 2022 Option Exercise$8.309668,01815,716Jan 14, 2022, 05:06 PM
MANHARD KIMBERLYEVP, Drug DevelopmentJan 13, 2022 Option Exercise$8.302,01216,7007,070Jan 14, 2022, 05:05 PM
POYHONEN JOHNPresident & CCOOct 29, 2021 Option Exercise$9.368177,64623,836Dec 23, 2021, 06:59 PM
Christian WaageDirectorDec 21, 2021 Sale$9.733002,9203,200Dec 23, 2021, 06:58 PM
Johnson Craig ADirectorDec 21, 2021 Sale$9.732502,4322,840Dec 23, 2021, 06:57 PM
Szekeres David LeslieEVP, Chief Operating OfficerOct 13, 2021 Option Exercise$10.554334,5683,981Oct 15, 2021, 04:26 PM
Quart Barry DChief Executive OfficerOct 13, 2021 Option Exercise$10.5596310,160102,086Oct 15, 2021, 04:25 PM
POYHONEN JOHNPresident & CCOOct 13, 2021 Option Exercise$10.554334,56823,019Oct 15, 2021, 04:24 PM
Peraza LisaVP, Chief Accounting OfficerOct 13, 2021 Option Exercise$10.551912,01514,197Oct 15, 2021, 04:23 PM
MANHARD KIMBERLYEVP, Drug DevelopmentOct 13, 2021 Option Exercise$10.554334,5683,268Oct 15, 2021, 04:22 PM
Christian WaageDirectorSep 21, 2021 Sale$12.313003,6923,500Sep 23, 2021, 04:30 PM
Johnson Craig ADirectorSep 21, 2021 Sale$12.302503,0743,090Sep 23, 2021, 04:29 PM
Szekeres David LeslieEVP, Chief Operating OfficerJul 13, 2021 Option Exercise$13.484335,8373,164Jul 15, 2021, 04:52 PM
Szekeres David LeslieEVP, Chief Operating OfficerApr 30, 2021 Option Exercise$13.901,53021,2632,347Jul 15, 2021, 04:52 PM
Quart Barry DChief Executive OfficerJul 13, 2021 Option Exercise$13.4896312,98199,403Jul 15, 2021, 04:50 PM
Quart Barry DChief Executive OfficerApr 30, 2021 Option Exercise$13.901,52921,24996,721Jul 15, 2021, 04:50 PM
POYHONEN JOHNPresident & CCOJul 13, 2021 Option Exercise$13.484335,83722,202Jul 15, 2021, 04:49 PM
POYHONEN JOHNPresident & CCOApr 30, 2021 Option Exercise$13.9097113,49421,385Jul 15, 2021, 04:49 PM
Peraza LisaVP, Chief Accounting OfficerJul 13, 2021 Option Exercise$13.481912,57513,836Jul 15, 2021, 04:48 PM
Peraza LisaVP, Chief Accounting OfficerApr 30, 2021 Option Exercise$13.901,53021,26313,475Jul 15, 2021, 04:48 PM
MANHARD KIMBERLYEVP, Drug DevelopmentJul 13, 2021 Option Exercise$13.484335,8372,451Jul 15, 2021, 04:47 PM
Johnson Craig ADirectorJun 21, 2021 Sale$15.202503,8013,340Jun 22, 2021, 05:05 PM
Christian WaageDirectorApr 15, 2021 Sale$17.513005,2544,100Apr 16, 2021, 08:59 PM
Szekeres David LeslieEVP, Chief Operating OfficerApr 13, 2021 Option Exercise$16.664337,214817Apr 15, 2021, 04:55 PM
Quart Barry DChief Executive OfficerApr 13, 2021 Option Exercise$16.6696316,04495,192Apr 15, 2021, 04:54 PM
POYHONEN JOHNPresident & CCOApr 13, 2021 Option Exercise$16.664337,21420,414Apr 15, 2021, 04:53 PM
Peraza LisaVP, Chief Accounting OfficerApr 13, 2021 Option Exercise$16.661913,18211,945Apr 15, 2021, 04:52 PM
MANHARD KIMBERLYEVP, Drug DevelopmentApr 13, 2021 Option Exercise$16.664337,2141,634Apr 15, 2021, 04:51 PM
Johnson Craig ADirectorApr 06, 2021 Sale$17.222504,3053,590Apr 07, 2021, 05:04 PM
Szekeres David LeslieEVP, Chief Operating OfficerJan 13, 2021 Option Exercise$18.164237,682827Jan 15, 2021, 04:30 PM
Szekeres David LeslieEVP, Chief Operating OfficerJan 14, 2021 Sale$18.0982714,9600Jan 15, 2021, 04:30 PM
Quart Barry DChief Executive OfficerJan 13, 2021 Option Exercise$18.1696317,48891,909Jan 15, 2021, 04:29 PM
POYHONEN JOHNPresident & CCOJan 13, 2021 Option Exercise$18.164337,86319,597Jan 15, 2021, 04:27 PM
Peraza LisaVP, Chief Accounting OfficerJan 13, 2021 Option Exercise$18.162274,12211,584Jan 15, 2021, 04:26 PM
MANHARD KIMBERLYEVP, Drug DevelopmentJan 13, 2021 Option Exercise$18.164337,863817Jan 15, 2021, 04:25 PM
Szekeres David LeslieEVP, Chief Operating OfficerJan 08, 2021 Sale$19.663,57170,2190Jan 08, 2021, 06:07 PM
POYHONEN JOHNPresident & CCOOct 30, 2020 Option Exercise$11.656377,42318,780Dec 23, 2020, 04:24 PM
MANHARD KIMBERLYEVP, Drug DevelopmentDec 22, 2020 Option Exercise$13.0010,000130,00010,000Dec 23, 2020, 04:23 PM
MANHARD KIMBERLYEVP, Drug DevelopmentDec 22, 2020 Sale$20.0010,000200,0000Dec 23, 2020, 04:23 PM
Quart Barry DChief Executive OfficerApr 30, 2020 Option Exercise$12.121,15814,03689,226Oct 15, 2020, 04:23 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentApr 30, 2020 Option Exercise$12.121,15814,0361,158May 01, 2020, 06:48 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentMay 01, 2020 Sale$13.971,15816,1760May 01, 2020, 06:48 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentNov 29, 2019 Option Exercise$13.0024,000312,00024,000Dec 03, 2019, 06:30 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentNov 29, 2019 Sale$26.0024,000624,0000Dec 03, 2019, 06:30 PM
TANG KEVIN CDirectorOct 04, 2019 Buy$17.50285,7144,999,9955,799,810Oct 07, 2019, 05:18 PM
Quart Barry DChief Executive OfficerApr 30, 2019 Option Exercise$18.4380614,85390,081Oct 04, 2019, 07:58 PM
Quart Barry DChief Executive OfficerOct 03, 2019 Buy$17.504,57179,99394,652Oct 04, 2019, 07:58 PM
POYHONEN JOHNEVP, Chief Commercial OfficerOct 03, 2019 Buy$17.505,14390,00318,143Oct 04, 2019, 07:56 PM
POYHONEN JOHNDirectorMay 22, 2019 Buy$17.553,00052,65013,000May 23, 2019, 08:39 AM
Christian WaageDirectorMay 15, 2019 Buy$18.041,40025,2621,400May 16, 2019, 08:44 AM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentApr 30, 2019 Option Exercise$18.431,10920,4371,109May 02, 2019, 08:40 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentMay 01, 2019 Sale$18.861,10920,9180May 02, 2019, 08:40 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentOct 31, 2018 Option Exercise$23.6049411,656494Nov 02, 2018, 09:17 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentNov 02, 2018 Sale$30.6249415,1250Nov 02, 2018, 09:17 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentOct 01, 2018 Option Exercise$13.006,00078,0006,000Oct 02, 2018, 09:12 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentOct 01, 2018 Sale$32.076,000192,4330Oct 02, 2018, 09:12 PM
Quart Barry DChief Executive OfficerSep 14, 2018 Option Exercise$7.2019,675141,66089,275Sep 14, 2018, 11:41 AM
TANG KEVIN CDirectorSep 12, 2018 Sale$35.752,695,00096,346,2505,830,215Sep 12, 2018, 12:28 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentJul 02, 2018 Option Exercise$13.006,00078,0006,000Jul 03, 2018, 09:05 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentJul 02, 2018 Sale$37.536,000225,179100Jul 03, 2018, 09:05 PM
HOFFMAN ROBERTCFO & SVP, FinanceApr 30, 2018 Option Exercise$13.227449,8341,280Jul 03, 2018, 09:03 PM
HOFFMAN ROBERTCFO & SVP, FinanceJul 02, 2018 Option Exercise$15.3030,000459,00031,280Jul 03, 2018, 09:03 PM
HOFFMAN ROBERTCFO & SVP, FinanceJul 02, 2018 Sale$38.1730,0001,145,2302,340Jul 03, 2018, 09:03 PM
Rosen RobertPresidentJul 02, 2018 Option Exercise$7.2095,531687,82398,171Jul 03, 2018, 09:01 PM
Rosen RobertPresidentJun 29, 2018 Option Exercise$7.20129,469932,177132,109Jul 03, 2018, 09:01 PM
Rosen RobertPresidentJul 02, 2018 Sale$38.1595,5313,644,6836,040Jul 03, 2018, 09:01 PM
Rosen RobertPresidentJun 29, 2018 Sale$39.59129,4695,125,13556,448Jul 03, 2018, 09:01 PM
Quart Barry DChief Executive OfficerApr 30, 2018 Option Exercise$13.221,60721,24169,600Jun 22, 2018, 09:35 PM
Quart Barry DChief Executive OfficerJun 21, 2018 Option Exercise$9.0550,000452,500119,600Jun 22, 2018, 09:35 PM
Quart Barry DChief Executive OfficerJun 21, 2018 Sale$39.0550,0001,952,50069,600Jun 22, 2018, 09:35 PM
TANG KEVIN CDirectorMar 29, 2018 Buy$26.00192,3085,000,0088,525,215Apr 02, 2018, 04:01 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentMar 19, 2018 Option Exercise$13.0018,000234,00018,000Mar 19, 2018, 07:24 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentMar 19, 2018 Sale$30.0018,000540,0000Mar 19, 2018, 07:24 PM
Quart Barry DChief Executive OfficerMar 19, 2018 Option Exercise$7.20100,000720,000167,993Mar 19, 2018, 07:22 PM
Quart Barry DChief Executive OfficerMar 19, 2018 Sale$29.75100,0002,975,00067,993Mar 19, 2018, 07:22 PM
Quart Barry DChief Executive OfficerMar 14, 2018 Option Exercise$7.20100,000720,000167,993Mar 16, 2018, 09:00 PM
Quart Barry DChief Executive OfficerMar 14, 2018 Sale$24.75100,0002,475,00067,993Mar 16, 2018, 09:00 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentJan 10, 2018 Option Exercise$13.007,58498,5927,584Jan 12, 2018, 04:21 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentJan 10, 2018 Sale$20.007,584151,6800Jan 12, 2018, 04:21 PM
Quart Barry DChief Executive OfficerApr 28, 2017 Option Exercise$12.621,68421,25667,993Dec 20, 2017, 04:15 PM
HOFFMAN ROBERTCFO & SVP, FinanceOct 31, 2017 Option Exercise$13.055366,993536Dec 20, 2017, 04:13 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentApr 24, 2017 Option Exercise$8.9921,542193,64321,542Apr 24, 2017, 08:58 PM
MANHARD KIMBERLYExecutive VP, Drug DevelopmentApr 24, 2017 Sale$15.3321,542330,2630Apr 24, 2017, 08:58 PM
POYHONEN JOHNDirectorJan 19, 2017 Buy$12.2010,000122,00010,000Jan 23, 2017, 04:29 PM
TANG KEVIN CDirectorJan 19, 2017 Buy$12.202,459,01629,999,9958,332,907Jan 23, 2017, 04:03 PM
Drazba Brian G.VP, Finance & CFOOct 31, 2016 Option Exercise$12.625386,7913,798Dec 23, 2016, 04:03 PM
Drazba Brian G.VP, Finance & CFOApr 29, 2016 Option Exercise$18.2257710,5153,260Dec 23, 2016, 04:03 PM
Rosen RobertPresident & CCOAug 10, 2016 Option Exercise$7.20100,000720,000102,640Aug 12, 2016, 05:14 PM
Rosen RobertPresident & CCOAug 10, 2016 Sale$23.30100,0002,329,89515,040Aug 12, 2016, 05:14 PM
Quart Barry DChief Executive OfficerApr 29, 2016 Option Exercise$18.2283715,25361,679Jul 20, 2016, 08:50 AM
Quart Barry DChief Executive OfficerJul 19, 2016 Option Exercise$7.204,63033,33666,309Jul 20, 2016, 08:50 AM
TANG KEVIN CDirectorJun 16, 2016 Option Exercise$18.47243,6394,500,0125,873,891Jun 20, 2016, 08:01 PM
TANG KEVIN CDirectorJun 16, 2016 Option Exercise$3.601,250,0004,500,0006,117,530Jun 20, 2016, 08:01 PM
Rosen RobertPresidentApr 20, 2016 Option Exercise$7.204,01028,8726,650Apr 21, 2016, 09:27 PM
Rosen RobertPresidentApr 19, 2016 Option Exercise$7.20176,3281,269,562178,968Apr 21, 2016, 09:27 PM
Rosen RobertPresidentApr 21, 2016 Option Exercise$7.2019,662141,56622,302Apr 21, 2016, 09:27 PM
Rosen RobertPresidentApr 19, 2016 Sale$23.38176,3284,122,022118,043Apr 21, 2016, 09:27 PM
Rosen RobertPresidentApr 21, 2016 Sale$22.1519,662435,4332,640Apr 21, 2016, 09:27 PM
Rosen RobertPresidentApr 20, 2016 Sale$22.194,01088,9672,640Apr 21, 2016, 09:27 PM
Marshall PaulSVP, Technical OperationsMar 21, 2016 Option Exercise$9.051,1009,9552,200Mar 23, 2016, 03:07 PM
Quart Barry DChief Executive OfficerMar 02, 2016 Option Exercise$7.203,47224,99860,842Mar 03, 2016, 08:01 AM
Marshall PaulSVP, Technical OperationsDec 29, 2015 Option Exercise$9.051,1009,9551,100Dec 30, 2015, 05:14 PM
Quart Barry DChief Executive OfficerDec 28, 2015 Option Exercise$7.202,31516,66882,370Dec 30, 2015, 05:13 PM
Drazba Brian G.VP, Finance & CFOOct 30, 2015 Option Exercise$9.367146,6822,683Dec 24, 2015, 12:29 PM
Drazba Brian G.VP, Finance & CFOApr 30, 2015 Option Exercise$7.601,1518,7461,969Dec 24, 2015, 12:29 PM
Quart Barry DChief Executive OfficerOct 14, 2015 Option Exercise$7.2010,00072,00080,055Oct 15, 2015, 08:02 AM
Quart Barry DChief Executive OfficerSep 29, 2015 Option Exercise$7.2014,306103,00370,055Sep 30, 2015, 08:51 AM
Quart Barry DChief Executive OfficerApr 30, 2015 Option Exercise$7.602,88121,89645,749Aug 19, 2015, 04:39 PM
Quart Barry DChief Executive OfficerAug 18, 2015 Option Exercise$7.2010,00072,00055,749Aug 19, 2015, 04:39 PM
TANG KEVIN CDirectorJun 10, 2015 Buy$24.75121,2122,999,9974,867,530Jun 12, 2015, 04:06 PM
MANHARD KIMBERLYDirectorJun 02, 2015 Option Exercise$8.8010,50092,40010,500Jun 03, 2015, 06:46 PM
MANHARD KIMBERLYDirectorJun 01, 2015 Option Exercise$9.052,70824,5072,708Jun 03, 2015, 06:46 PM
MANHARD KIMBERLYDirectorJun 02, 2015 Sale$23.5810,500247,5900Jun 03, 2015, 06:46 PM
MANHARD KIMBERLYDirectorJun 01, 2015 Sale$21.172,70857,3280Jun 03, 2015, 06:46 PM
TANG KEVIN CDirectorJun 01, 2015 Buy$19.302,38045,9344,713,923Jun 02, 2015, 04:01 PM
TANG KEVIN CDirectorMay 29, 2015 Buy$19.74115,2252,274,0584,711,543Jun 02, 2015, 04:01 PM
TANG KEVIN CDirectorJun 02, 2015 Buy$23.8432,395772,2944,746,318Jun 02, 2015, 04:01 PM
Marshall PaulSVP, Technical OperationsMar 05, 2015 Option Exercise$9.4070,000658,00070,000Mar 09, 2015, 07:02 PM
Marshall PaulSVP, Technical OperationsMar 05, 2015 Sale$14.6970,0001,028,00020,000Mar 09, 2015, 07:02 PM
Quart Barry DChief Executive OfficerMar 02, 2015 Sale$13.0710,000130,72742,868Mar 04, 2015, 06:52 PM
Quart Barry DChief Executive OfficerOct 31, 2014 Option Exercise$7.501,94114,55263,796Dec 15, 2014, 09:03 PM
Drazba Brian G.VP, Finance & CFOOct 31, 2014 Option Exercise$7.508186,133818Dec 15, 2014, 08:58 PM
DAVIS STEPHENDirectorSep 26, 2014 Option Exercise$8.44102,634866,23120,076Sep 30, 2014, 06:41 PM
DAVIS STEPHENDirectorSep 26, 2014 Option Exercise$7.20120,313866,254122,710Sep 30, 2014, 06:41 PM
TANG KEVIN CDirectorJun 25, 2014 Buy$11.75510,6385,999,9974,596,318Jun 27, 2014, 04:01 PM
Quart Barry DChief Executive OfficerJun 25, 2014 Buy$11.7510,000117,50061,855Jun 26, 2014, 06:48 PM
TANG KEVIN CDirectorNov 20, 2013 Option Exercise$0.4017,500,0007,000,00081,713,600Nov 22, 2013, 05:02 PM
Quart Barry DChief Executive OfficerNov 20, 2013 Buy$0.401,000,000400,0001,037,100Nov 21, 2013, 03:57 PM
Whelan JohnCFOJul 18, 2013 Option Exercise$0.26254,08866,063254,088Jul 19, 2013, 07:21 PM
SPCH, LLLP10% OwnerJul 25, 2012 Buy$0.5238,095,23819,999,99938,095,238Sep 12, 2012, 05:05 PM
TANG KEVIN CDirectorJul 25, 2012 Option Exercise$0.529,523,8105,000,00069,960,316Jul 27, 2012, 07:16 PM
TANG KEVIN CDirectorJun 29, 2011 Option Exercise$0.1550,000,0007,500,00060,436,506Jul 01, 2011, 04:22 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Duarte IraEVP, Chief Financial Officer04/19/20242,962
Peraza LisaVP, Chief Accounting Officer01/13/20241,625
Forbes William PEVP, Chief Development Officer11/17/202327,250
Forbes William PEVP, Chief Development Officer11/16/202346,995
Collard Craig AChief Executive Officer11/16/2023137,970
Duarte IraEVP, Chief Financial Officer11/16/202375,599
Peraza LisaVP, Chief Accounting Officer07/25/202322,262
Peraza LisaVP, Chief Accounting Officer10/13/2023619
Collard Craig AChief Executive Officer08/22/20231,142
Morgan AdamDirector07/21/20233,406,839
Szekeres David LeslieEVP, Chief Operating Officer07/13/20232,636
Peraza LisaVP, Chief Accounting Officer07/13/20231,127
Collard Craig AChief Executive Officer05/22/20231,002
Szekeres David LeslieEVP, Chief Operating Officer04/13/20235,795
POYHONEN JOHNPresident & CCO04/13/20235,795
Peraza LisaVP, Chief Accounting Officer04/13/20232,477
MANHARD KIMBERLYEVP, Drug Development04/13/20234,081
Szekeres David LeslieEVP, Chief Operating Officer01/13/20236,378
Szekeres David LeslieEVP, Chief Operating Officer10/31/20225,413
Quart Barry DChief Executive Officer01/13/202316,544
Quart Barry DChief Executive Officer10/31/20225,416
POYHONEN JOHNPresident & CCO01/13/20236,378
Peraza LisaVP, Chief Accounting Officer01/13/20233,211
MANHARD KIMBERLYEVP, Drug Development01/13/20236,378
MANHARD KIMBERLYEVP, Drug Development10/31/20225,416
Szekeres David LeslieEVP, Chief Operating Officer10/13/20227,565
Quart Barry DChief Executive Officer10/13/202219,623
POYHONEN JOHNPresident & CCO10/13/20227,565
Peraza LisaVP, Chief Accounting Officer10/13/20223,237
MANHARD KIMBERLYEVP, Drug Development10/13/20227,565
Szekeres David LeslieEVP, Chief Operating Officer07/13/20226,056
Szekeres David LeslieEVP, Chief Operating Officer04/29/20225,782
Quart Barry DChief Executive Officer07/13/202215,709
Quart Barry DChief Executive Officer04/29/20225,778
POYHONEN JOHNPresident & CCO07/13/20226,056
Peraza LisaVP, Chief Accounting Officer07/13/20222,589
MANHARD KIMBERLYEVP, Drug Development07/13/20226,056
MANHARD KIMBERLYEVP, Drug Development04/29/20225,778
MANHARD KIMBERLYEVP, Drug Development05/03/20227,154
Szekeres David LeslieEVP, Chief Operating Officer04/13/202212,213
Quart Barry DChief Executive Officer04/13/202231,679
POYHONEN JOHNPresident & CCO04/13/202212,213
Peraza LisaVP, Chief Accounting Officer04/13/20225,220
MANHARD KIMBERLYEVP, Drug Development04/13/202212,213
Szekeres David LeslieEVP, Chief Operating Officer01/13/202216,700
Quart Barry DChief Executive Officer01/13/202243,318
POYHONEN JOHNPresident & CCO01/13/202216,700
Peraza LisaVP, Chief Accounting Officer01/13/20228,018
MANHARD KIMBERLYEVP, Drug Development01/13/202216,700
POYHONEN JOHNPresident & CCO10/29/20217,646
Christian WaageDirector12/21/20212,920
Johnson Craig ADirector12/21/20212,432
Szekeres David LeslieEVP, Chief Operating Officer10/13/20214,568
Quart Barry DChief Executive Officer10/13/202110,160
POYHONEN JOHNPresident & CCO10/13/20214,568
Peraza LisaVP, Chief Accounting Officer10/13/20212,015
MANHARD KIMBERLYEVP, Drug Development10/13/20214,568
Christian WaageDirector09/21/20213,692
Johnson Craig ADirector09/21/20213,074
Szekeres David LeslieEVP, Chief Operating Officer07/13/20215,837
Szekeres David LeslieEVP, Chief Operating Officer04/30/202121,263
Quart Barry DChief Executive Officer07/13/202112,981
Quart Barry DChief Executive Officer04/30/202121,249
POYHONEN JOHNPresident & CCO07/13/20215,837
POYHONEN JOHNPresident & CCO04/30/202113,494
Peraza LisaVP, Chief Accounting Officer07/13/20212,575
Peraza LisaVP, Chief Accounting Officer04/30/202121,263
MANHARD KIMBERLYEVP, Drug Development07/13/20215,837
Johnson Craig ADirector06/21/20213,801
Christian WaageDirector04/15/20215,254
Szekeres David LeslieEVP, Chief Operating Officer04/13/20217,214
Quart Barry DChief Executive Officer04/13/202116,044
POYHONEN JOHNPresident & CCO04/13/20217,214
Peraza LisaVP, Chief Accounting Officer04/13/20213,182
MANHARD KIMBERLYEVP, Drug Development04/13/20217,214
Johnson Craig ADirector04/06/20214,305
Szekeres David LeslieEVP, Chief Operating Officer01/13/20217,682
Szekeres David LeslieEVP, Chief Operating Officer01/14/202114,960
Quart Barry DChief Executive Officer01/13/202117,488
POYHONEN JOHNPresident & CCO01/13/20217,863
Peraza LisaVP, Chief Accounting Officer01/13/20214,122
MANHARD KIMBERLYEVP, Drug Development01/13/20217,863
Szekeres David LeslieEVP, Chief Operating Officer01/08/202170,219
POYHONEN JOHNPresident & CCO10/30/20207,423
MANHARD KIMBERLYEVP, Drug Development12/22/2020130,000
MANHARD KIMBERLYEVP, Drug Development12/22/2020200,000
Quart Barry DChief Executive Officer04/30/202014,036
MANHARD KIMBERLYExecutive VP, Drug Development04/30/202014,036
MANHARD KIMBERLYExecutive VP, Drug Development05/01/202016,176
MANHARD KIMBERLYExecutive VP, Drug Development11/29/2019312,000
MANHARD KIMBERLYExecutive VP, Drug Development11/29/2019624,000
TANG KEVIN CDirector10/04/20194,999,995
Quart Barry DChief Executive Officer04/30/201914,853
Quart Barry DChief Executive Officer10/03/201979,993
POYHONEN JOHNEVP, Chief Commercial Officer10/03/201990,003
POYHONEN JOHNDirector05/22/201952,650
Christian WaageDirector05/15/201925,262
MANHARD KIMBERLYExecutive VP, Drug Development04/30/201920,437
MANHARD KIMBERLYExecutive VP, Drug Development05/01/201920,918
MANHARD KIMBERLYExecutive VP, Drug Development10/31/201811,656
MANHARD KIMBERLYExecutive VP, Drug Development11/02/201815,125
MANHARD KIMBERLYExecutive VP, Drug Development10/01/201878,000
MANHARD KIMBERLYExecutive VP, Drug Development10/01/2018192,433
Quart Barry DChief Executive Officer09/14/2018141,660
TANG KEVIN CDirector09/12/201896,346,250
MANHARD KIMBERLYExecutive VP, Drug Development07/02/201878,000
MANHARD KIMBERLYExecutive VP, Drug Development07/02/2018225,179
HOFFMAN ROBERTCFO & SVP, Finance04/30/20189,834
HOFFMAN ROBERTCFO & SVP, Finance07/02/2018459,000
HOFFMAN ROBERTCFO & SVP, Finance07/02/20181,145,230
Rosen RobertPresident07/02/2018687,823
Rosen RobertPresident06/29/2018932,177
Rosen RobertPresident07/02/20183,644,683
Rosen RobertPresident06/29/20185,125,135
Quart Barry DChief Executive Officer04/30/201821,241
Quart Barry DChief Executive Officer06/21/2018452,500
Quart Barry DChief Executive Officer06/21/20181,952,500
TANG KEVIN CDirector03/29/20185,000,008
MANHARD KIMBERLYExecutive VP, Drug Development03/19/2018234,000
MANHARD KIMBERLYExecutive VP, Drug Development03/19/2018540,000
Quart Barry DChief Executive Officer03/19/2018720,000
Quart Barry DChief Executive Officer03/19/20182,975,000
Quart Barry DChief Executive Officer03/14/2018720,000
Quart Barry DChief Executive Officer03/14/20182,475,000
MANHARD KIMBERLYExecutive VP, Drug Development01/10/201898,592
MANHARD KIMBERLYExecutive VP, Drug Development01/10/2018151,680
Quart Barry DChief Executive Officer04/28/201721,256
HOFFMAN ROBERTCFO & SVP, Finance10/31/20176,993
MANHARD KIMBERLYExecutive VP, Drug Development04/24/2017193,643
MANHARD KIMBERLYExecutive VP, Drug Development04/24/2017330,263
POYHONEN JOHNDirector01/19/2017122,000
TANG KEVIN CDirector01/19/201729,999,995
Drazba Brian G.VP, Finance & CFO10/31/20166,791
Drazba Brian G.VP, Finance & CFO04/29/201610,515
Rosen RobertPresident & CCO08/10/2016720,000
Rosen RobertPresident & CCO08/10/20162,329,895
Quart Barry DChief Executive Officer04/29/201615,253
Quart Barry DChief Executive Officer07/19/201633,336
TANG KEVIN CDirector06/16/20164,500,012
TANG KEVIN CDirector06/16/20164,500,000
Rosen RobertPresident04/20/201628,872
Rosen RobertPresident04/19/20161,269,562
Rosen RobertPresident04/21/2016141,566
Rosen RobertPresident04/19/20164,122,022
Rosen RobertPresident04/21/2016435,433
Rosen RobertPresident04/20/201688,967
Marshall PaulSVP, Technical Operations03/21/20169,955
Quart Barry DChief Executive Officer03/02/201624,998
Marshall PaulSVP, Technical Operations12/29/20159,955
Quart Barry DChief Executive Officer12/28/201516,668
Drazba Brian G.VP, Finance & CFO10/30/20156,682
Drazba Brian G.VP, Finance & CFO04/30/20158,746
Quart Barry DChief Executive Officer10/14/201572,000
Quart Barry DChief Executive Officer09/29/2015103,003
Quart Barry DChief Executive Officer04/30/201521,896
Quart Barry DChief Executive Officer08/18/201572,000
TANG KEVIN CDirector06/10/20152,999,997
MANHARD KIMBERLYDirector06/02/201592,400
MANHARD KIMBERLYDirector06/01/201524,507
MANHARD KIMBERLYDirector06/02/2015247,590
MANHARD KIMBERLYDirector06/01/201557,328
TANG KEVIN CDirector06/01/201545,934
TANG KEVIN CDirector05/29/20152,274,058
TANG KEVIN CDirector06/02/2015772,294
Marshall PaulSVP, Technical Operations03/05/2015658,000
Marshall PaulSVP, Technical Operations03/05/20151,028,000
Quart Barry DChief Executive Officer03/02/2015130,727
Quart Barry DChief Executive Officer10/31/201414,552
Drazba Brian G.VP, Finance & CFO10/31/20146,133
DAVIS STEPHENDirector09/26/2014866,231
DAVIS STEPHENDirector09/26/2014866,254
TANG KEVIN CDirector06/25/20145,999,997
Quart Barry DChief Executive Officer06/25/2014117,500
TANG KEVIN CDirector11/20/20137,000,000
Quart Barry DChief Executive Officer11/20/2013400,000
Whelan JohnCFO07/18/201366,063
SPCH, LLLP10% Owner07/25/201219,999,999
TANG KEVIN CDirector07/25/20125,000,000
TANG KEVIN CDirector06/29/20117,500,000
Load More Insider Transactions
FUNDS WITH A POSITION IN HERON THERAPEUTICS INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BLACKROCK INC.7,286,0280.00047%1.73%Other
ORBIMED ADVISORS LLC5,928,5910.2%638.58%Other
ADAGE CAPITAL PARTNERS GP, L.L.C.2,910,0110.01%45.5%Other
GEODE CAPITAL MANAGEMENT, LLC2,624,6740.00047%9.58%Other
RENAISSANCE TECHNOLOGIES LLC1,883,3000.00496%546.52%Other
D. E. SHAW & CO., INC.1,290,9970.00192%426.35%Other
NEXPOINT ASSET MANAGEMENT, L.P.475,7500.12%-4.68%Event Driven, Value
AQR CAPITAL MANAGEMENT LLC36,8550.00012%-69.98%Other
CHANGE IN SHARES OUTSTANDING FOR HERON THERAPEUTICS INC
STOCK BUYBACKS FOR HERON THERAPEUTICS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
12/31/2023
09/30/2023
4.35%
1Q
12/31/2023
06/30/2023
26.38%
2Q
12/31/2023
03/31/2023
26.88%
3Q
12/31/2023
12/31/2022
27.00%
4Q
12/31/2023
09/30/2022
35.41%
5Q
12/31/2023
06/30/2022
47.75%
6Q
12/31/2023
03/31/2022
48.15%
7Q
12/31/2023
12/31/2021
48.31%
8Q
12/31/2023
09/30/2021
48.47%
9Q
12/31/2023
06/30/2021
53.67%
10Q
12/31/2023
03/31/2021
65.56%
11Q
12/31/2023
12/31/2020
66.11%
12Q
12/31/2023
09/30/2020
66.54%
13Q
12/31/2023
06/30/2020
66.72%
14Q
12/31/2023
03/31/2020
67.35%
15Q
12/31/2023
12/31/2019
69.63%
16Q
Load More

Period of Report: 12/31/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
09/30/2023
4.35%
1Q
06/30/2023
26.38%
2Q
03/31/2023
26.88%
3Q
12/31/2022
27.00%
4Q
09/30/2022
35.41%
5Q
06/30/2022
47.75%
6Q
03/31/2022
48.15%
7Q
12/31/2021
48.31%
8Q
09/30/2021
48.47%
9Q
06/30/2021
53.67%
10Q
03/31/2021
65.56%
11Q
12/31/2020
66.11%
12Q
09/30/2020
66.54%
13Q
06/30/2020
66.72%
14Q
03/31/2020
67.35%
15Q
12/31/2019
69.63%
16Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR HERON THERAPEUTICS INC
LOADING...